|
|
| (3 intermediate revisions by one other user not shown) |
| Line 1: |
Line 1: |
| __NOTOC__
| | #REDIRECT [[Methyldopa#Warnings]] |
| {{Methyldopa}}
| |
| {{CMG}}; {{AE}} {{AK}}
| |
| | |
| ==PRECAUTIONS==
| |
| | |
| ===General===
| |
| | |
| Methyldopa should be used with caution in patients with a history of previous liver disease or dysfunction (see [[Methyldopa tablet warnings|WARNINGS]]).
| |
| Some patients taking methyldopa experience clinical [[edema ]]or weight gain which may be controlled by use of a [[diuretic]]. Methyldopa should not be continued if edema progresses or signs of heart failure appear.
| |
| | |
| [[Hypertension ]]has recurred occasionally after [[dialysis ]]in patients given methyldopa because the drug is removed by this procedure.
| |
| | |
| Rarely, involuntary choreoathetotic movements have been observed during therapy with methyldopa in patients with severe bilateral cerebrovascular disease. Should these movements occur, stop therapy.
| |
| | |
| ===Laboratory Tests===
| |
| | |
| Blood count, [[Coombs test]] and liver function tests are recommended before initiating therapy and at periodic intervals (see [[Methyldopa tablet warnings|WARNINGS]]).
| |
| ===Drug Interactions===
| |
| | |
| When methyldopa is used with other [[antihypertensive ]]drugs, potentiation of antihypertensive effect may occur. Patients should be followed carefully to detect side reactions or unusual manifestations of drug idiosyncrasy.
| |
| | |
| Patients may require reduced doses of anesthetics when on methyldopa. If hypotension does occur during [[anesthesia]], it usually can be controlled by [[vasopressors]]. The adrenergic receptors remain sensitive during treatment with methyldopa.
| |
| | |
| When methyldopa and lithium are given concomitantly, the patient should be carefully monitored for symptoms of lithium toxicity. Read the circular for [[lithium ]]preparations.
| |
| | |
| Several studies demonstrate a decrease in the bioavailability of methyldopa when it is ingested with [[ferrous sulfate]] or [[ferrous gluconate]]. This may adversely affect blood pressure control in patients treated with methyldopa. Coadministration of methyldopa with ferrous sulfate or ferrous gluconate is not recommended.
| |
| | |
| [[Monoamine oxidase]] (MAO) inhibitors: See CONTRAINDICATIONS.
| |
| | |
| ===Drug/Laboratory Test Interactions===
| |
| | |
| Methyldopa may interfere with measurement of: urinary uric acid by the phosphotungstate method, serum [[creatinine ]]by the alkaline picrate method, and [[SGOT ]]by colorimetric methods. Interference with spectrophotometric methods for [[SGOT ]]analysis has not been reported.
| |
| | |
| Since methyldopa causes fluorescence in urine samples at the same wave lengths as catecholamines, falsely high levels of urinary [[catecholamines ]]may be reported. This will interfere with the diagnosis of [[pheochromocytoma]]. It is important to recognize this phenomenon before a patient with a possible pheochromocytoma is subjected to surgery. Methyldopa does not interfere with measurement of VMA ([[vanillylmandelic acid]]), a test for pheochromocytoma, by those methods which convert VMA to vanillin. Methyldopa is not recommended for the treatment of patients with [[pheochromocytoma]]. Rarely, when urine is exposed to air after voiding, it may darken because of breakdown of methyldopa or its metabolites.<ref name="dailymed.nlm.nih.gov">{{Cite web | last = | first = | title = METHYLDOPA TABLET [CARDINAL HEALTH] | url = http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=d87d63fd-48f7-4130-af03-5e263c338fe4 | publisher = | date = | accessdate = 10 March 2014 }}</ref>
| |
| | |
| | |
| | |
| | |
| ==References==
| |
| | |
| {{Reflist|2}}
| |
| | |
| [[Category:Cardiovascular Drugs]]
| |
| [[Category:Drugs]]
| |